News

Intermittent fasting may offer a new way to ease the dry eye symptoms that commonly affect people with Sjögren’s disease, according to a new study in mice. The alternating fasting and eating regimen was found to restore a healthier gut environment in the animals. This shift ultimately reduced immune…

Among people with Sjögren’s disease, those diagnosed before age 45 may face an increased risk of unusually high antibody levels in the blood and chronic lung disease, according to a study of more than 5,000 patients in China. Researchers linked these features to a distinct pattern of immune cells…

A self-perpetuating loop where T-cells and B-cells continuously activate each other may contribute to the development of Sjögren’s disease, according to a cell-based study that uncovers a potential new target for selective therapies. Led by scientists at Keio University School of Medicine, in Tokyo, Japan, a research team analyzed…

Efgartigimod, a treatment approved for certain autoimmune diseases, was linked to maintained clinical responses and low disease activity scores for up to 72 weeks in people with Sjögren’s disease, according to data from a small Phase 2 clinical trial and its open-label extension study. Participants who showed a clinical…

People with primary Sjögren’s disease and their close family members have a higher risk of developing cancer than the general population, according to a study out of Turkey. While Sjögren’s has been associated with a higher risk of cancer, the potential risk among family members is a new…

Through detailed computer-based analyses of publicly available genetic data sets, a team of scientists in China has identified three genes that are overactive in people with Sjögren’s disease, according to a study. The scientists are hopeful that, with further validation, these genes may be used as markers to aid…

A global clinical trial testing Immunovant’s injection therapy IMVT-1402 against a placebo in adults with Sjögren’s disease is still recruiting participants, and remains on track to provide initial data in 2028. That’s according to a press release from the company, a Roivant subsidiary, announcing Immunovant’s latest…

Dianthus Therapeutics has selected Sjögren’s disease as one of the first three priority indications for the clinical development of DNTH212, its experimental therapy for autoimmune conditions. The treatment is currently being tested in healthy adult volunteers in a China-based Phase 1 clinical trial (NCT07323173), with top-line data…

Efgartigimod, a therapy approved for certain autoimmune diseases, led to higher response rates and greater reductions in certain immune markers than a placebo in adults with Sjögren’s disease, according to final data from a small proof-of-concept clinical trial. Because the Phase 2 study, called RHO (NCT05817669), was not…

Women and men with Sjögren’s disease may experience the condition differently, particularly in the type and severity of symptoms and the organs affected, a study in the Netherlands suggests. While women were more likely to report dry eyes and dry mouth — the hallmark Sjögren’s symptoms — and…